Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Breast-01 pumitamig plus chemotherapy in first-line triple-negative breast cancer
NL-OMON59742Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) and breast cancer comparing pumitamig + chemotherapy with placebo + chemotherapy (2 arms). Primary endpoints: Overall survival and Progression-free survival by BICR. Started Aug 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NL-OMON59742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59742.